Company
Incyte
Incyte has 32 drugs tracked on RxWires: 10 in Phase 3, 7 in Phase 2, 5 in Phase 1/2, 10 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Tafasitamab | Phase 3 | Diffuse Large B-cell Lymphoma |
| Ruxolitinib | Phase 3 | Graft-versus-host Disease (GVHD) |
| INCB161734 | Phase 3 | Solid Tumors |
| Povorcitinib | Phase 3 | NonSegmental Vitiligo |
| INCA034176 | Phase 3 | Chronic Graft-versus-host-disease |
| INCA033989 | Phase 3 | Essential Thrombocythemia |
| INCA33890 | Phase 3 | CRC (Colorectal Cancer) |
| Methotrexate (MTX) | Phase 3 | Graft-versus-host Disease (GVHD) |
| parsaclisib | Phase 3 | Myelofibrosis |
| Pembrolizumab | Phase 3 | UC (Urothelial Cancer) |
| Pemigatinib | Phase 2 | Metastatic Urothelial Carcinoma |
| Itacitinib | Phase 2 | Adults Patients Having Non Severe HLH |
| INCA000585 | Phase 2 | Immune Thrombocytopenia |
| INCB000928 | Phase 2 | Fibrodysplasia Ossificans Progressiva (FOP) |
| Epacadostat | Phase 2 | Sarcoma |
| Biospecimen Collection | Phase 2 | Grade 3b Follicular Lymphoma |
| Rituximab | Phase 2 | Classic Follicular Lymphoma |
| INCB054329 Monotherapy | Phase 1/2 | Solid Tumors and Hematologic Malignancy |
| ASTX727 | Phase 1/2 | MDS/MPN |
| Retifanlimab | Phase 1/2 | Soft Tissue Sarcoma |
| Azacitidine | Phase 1/2 | Solid Tumors |
| INCB177054 | Phase 1/2 | Solid Tumors |
| INCA036873 | Phase 1 | Solid Tumors |
| Neoantigen Vaccine with Poly-ICLC adjuvant | Phase 1 | Pancreatic Cancer Metastatic |
| INCB001158 | Phase 1 | Metastatic Cancer |
| INCB099318 | Phase 1 | Advanced Solid Tumors |
| INCA035784 | Phase 1 | Myeloproliferative Neoplasms |
| INCA036978 | Phase 1 | Myeloproliferative Neoplasms |
| Axatilimab | Phase 1 | Healthy Participants |
| INCB054707 | Phase 1 | Renal Insufficiency |
| INCB160058 | Phase 1 | Myeloproliferative Neoplasms |
| INCB099280 | Phase 1 | Advanced Solid Tumors |
Latest
- Incb000928 moved to Phase 2
- Inca033989 moved to Phase 3
- incyte filed 8-K
- incyte filed 8-K
- incyte filed 8-K
Follow Incyte on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.